18th Feb 2026 16:40
Reference is made to the Extraordinary General Meeting in Aqua Bio Technology ASA ("ABTEC" or the "Company") on 16 February 2026 regarding the share capital increase in connection with the reverse share split (50:1). The Company's share capital shall be increased by NOK 3.30 through the issuance of 33 new shares, each with a par value of NOK 0.10, to facilitate the reverse share split. Kristian Flaten, CEO and CFO of Aqua Bio Technology ASA, has subscribed for and been allocated 33 new shares at a price of NOK 0.25 per share. Following this transaction, Flaten holds 33 shares in ABTEC. In addition, Caprock AS, a company closely associated with Flaten, was allocated ABTEC shares of NOK 300,000 (equal to 60,000 shares after the reverse share split) in the private placement, to be registered after the reverse share split (ref notice 13 February 2026).
This information is subject to the disclosure requirements pursuant to MAR article 19.
ContactsKristian FlatenCEO & CFOAqua Bio Technology ASA
Phone: +47 9509 2322Email: [email protected]
About UsAqua Bio Technology ASA (ABTEC) is a technology and distribution group in skincare and nonfood. The group has distribution towards B2C and B2B, and offers freight, customs, and logistics services. The group also develops sustainable biotechnology for use in skincare products. Aqua Bio Technology is listed on Euronext Expand Oslo.
This notice is published by Kristian Flaten on the listed date and time.
This information has been submitted pursuant to the Securities Trading Act § 5-12 and MAR Article 17. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-02-18 17:40 CET.
AttachmentsAqua Bio Technology ASA: Primary insider notification260218 ABTEC KRT1500 KF